EURETINA 2023: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial

News
Article

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"

The 23rd annual EURETINA Congress is underway in Amsterdam, the Netherlands. We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."

Here's what he had to say about the meeting and his research.

Audio Transcript

Editor's note - This transcript has been edited for clarity.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.